**NSE/BSE Listed Entity | Part of the Maneesh Pharmaceuticals Group** Phaarmasia Limited is a specialized Indian pharmaceutical manufacturer focused on the high-barrier niche of hormonal and steroidal formulations. As a key subsidiary within the **Maneesh Pharmaceuticals Group**, the company serves as a dedicated production hub for oral contraceptives and essential health supplements for both the **Indian Ministry of Health & Family Welfare** and diverse international markets. --- ### Specialized Product Portfolio & Therapeutic Focus Phaarmasia operates within a single reportable segment: the manufacturing and marketing of pharmaceutical formulations and cosmetics. The company has carved out a defensive niche in women’s healthcare and hormonal therapy. * **Core Formulations:** Primary production focuses on **Oral Contraceptive Pills (OCP)** and **Combipacks featuring Iron Tablets**. * **Ancillary Lines:** Production of other hormonal/steroidal formulations and a dedicated line for **Cosmetics**. * **Quality Benchmarks:** The company maintains **WHO-GMP** and **ISO 9001** certifications, adhering to the operational philosophy: **"DO IT RIGHT FIRST TIME, EVERY TIME."** --- ### Manufacturing Infrastructure & Digital Security The company’s technical infrastructure is specifically engineered to handle the sensitivities of steroidal production, where the prevention of cross-contamination is a critical regulatory and safety requirement. * **Production Capacity:** The facilities boast an annual capacity exceeding **3 Crore units**. * **Strategic Footprint:** While the registered office is located in **Hyderabad**, core operations are centralized in **Mumbai**. * **Land Assets:** The company holds **1,233.14 Square Meters** of land for **Unit II** on a long-term **80-year lease**. * **Data Integrity:** To protect proprietary formulations and clinical data, the company employs **end-to-end encryption** and security protocols aligned with **CERT-In** (Indian Computer Emergency Response Team) standards. --- ### Financial Performance & Recovery Trajectory Recent fiscal years have seen Phaarmasia navigating a volatile environment. While the company has faced persistent net losses, the most recent audited cycles indicate a stabilization in revenue and a significant narrowing of deficits. | Metric (₹ in Crore) | FY 2024-25 (Est/Prov) | FY 2023-24 | FY 2022-23 | | :--- | :---: | :---: | :---: | | **Gross Revenue** | **24.37** | **30.59** | **27.49** | | **Total Income (Lakhs)** | — | **3,125.49** | **2,800.57** | | **Net Profit / (Loss) (Crore)** | **(1.59)** | **(0.52)** | **(1.26)** | | **Earnings Per Share (EPS)** | — | **₹(0.83)** | **₹(1.84)** | **Key Financial Observations:** * **Loss Reduction:** In FY 2023-24, the company successfully reduced its net loss by approximately **59%** compared to the previous year. * **Liquidity Position:** As of March 31, 2024, the company maintained a healthy cash-to-debt ratio. **Cash and Cash Equivalents** stood at **₹48.73 Lakhs**, comfortably exceeding total borrowings and lease liabilities of **₹14.41 Lakhs**. * **Capital Base:** The **Equity Share Capital** remains stable at **₹682.70 Lakhs**. --- ### Corporate Structure & Ecosystem Synergy Phaarmasia functions as a vital node within a larger pharmaceutical ecosystem. It operates without subsidiaries of its own but relies heavily on its promoter group for scale and market reach. * **Ownership Structure:** * **Maneesh Pharmaceuticals Limited:** Holds a **44.22%** stake (Holding Company). * **Svizera Labs Private Limited:** Holds a **29.3%** stake (Associate). * **Related Party Dynamics:** The company utilizes an **Omnibus Approval** (up to **₹100 Crores** for FY 2024-25) to facilitate seamless transactions with group entities. This ensures production efficiency and raw material security. * **Inter-company Trade (FY 2023-24):** * Purchases/Services from Maneesh Pharma: **2,031.82 Lakhs**. * Sales to Maneesh Pharma: **913.11 Lakhs**. --- ### Strategic Pivot: Asset Optimization & Market Expansion The Board is currently executing a transition strategy to improve financial flexibility and focus on high-growth domestic opportunities. **1. Real Estate Divestment:** The company is actively streamlining its physical footprint. In **February 2025**, the Board authorized Managing Director **Mr. Vinay Sapte** to identify buyers for **Unit I (Plot No. 16)** in Jeedimetla, Hyderabad. This sale is intended to unlock capital and reduce overhead. **2. Growth Pillars:** * **Domestic Market Penetration:** Shifting focus toward Pan-India activity expansion and opportunistic investments. * **R&D and Innovation:** Leveraging research and development to introduce new therapeutic variations in the hormonal segment to counter pricing pressure. * **Strategic Partnerships:** Exploring domestic and global collaborations to diversify revenue streams beyond government tenders. --- ### Risk Profile & Mitigation Framework Phaarmasia operates in a high-risk, high-reward regulatory environment. Management has identified several key areas requiring robust oversight: **Operational & Financial Risks:** * **Asset Recovery Actions:** In 2023, **Pegasus Assets Reconstruction** initiated SARFAESI Act proceedings to recover **₹1.61 Crore** plus interest via mortgaged property. * **Cost Volatility:** Rising raw material costs drove expenses to **₹29.44 Crore** in FY 2022-23, necessitating stricter operational efficiency. * **Market Risks:** Exposure to **foreign exchange fluctuations** and **interest rate volatility** is managed through a Board-level risk management framework. **Regulatory & Compliance Challenges:** The company has historically faced challenges regarding **SEBI (LODR)** compliance, including: * **Disclosure Lapses:** Delays in filing annual reports to the **BSE** and failure to maintain a functional website per **Regulation 46**. * **Secretarial Standards:** Non-filing of **Form MGT-14** for the 2023-24 Directors' report. * **Legislative Impact:** The upcoming **Code on Social Security, 2020** may increase long-term liabilities regarding **Provident Fund** and **Gratuity** contributions. --- ### Governance & Leadership The company is governed by a **six-member Board**, structured to provide balanced oversight: * **Executive Leadership:** **Mr. Naga Bhaskara Rao Yallapragada** (Whole-time Director, re-appointed September 2024) and **Mr. N E V Prasad Rao** (CFO). * **Independent Oversight:** Two Independent Directors chair the Audit Committee, which is tasked with evaluating internal financial controls and mitigating credit and liquidity risks. * **Going Concern Status:** Despite recent losses and regulatory fines, no material orders have been passed by courts or regulators that threaten the company’s fundamental status as a **going concern**.